In Canada, More Mandatory Switching
In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.
Alvotech Gains EC Approval for Adalimumab Biosimilar
Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.
Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?
Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.
Poll: Identify the Main Cause for Reverse Switching
Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.
Poll: Where Do You Stand on Product Exclusivity Protections?
When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.
Poll: How Much Progress With Biosimilars Has the United States Made?
With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization.
Poll: What Is the Best Way to Improve Biosimilar Access?
Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.
Poll: How Can Patients Be Persuaded to Accept Biosimilars?
Opinions differ on what patients are more likely to respond to.
Harvard Paper: CMS Coding, Other Factors at Fault for Tepid Biosimilar Savings
Biosimilars are intended to save money for the health care system, but for many reasons, they are not succeeding in this mission, Harvard authors argue.
Poll: How Much Discretion Should Payers Have Over Biosimilar Coverage?
Coverage policies for biosimilars in the health care industry are the source of much angst.
Biosimilars Quiz: Which years have brought AbbVie the highest revenues for adalimumab?
Poll: What Will Be the Strongest Trend in 2021?
Which of these selections do you think is the most powerful trend in medicine to emerge from the pandemic?
Poll: How Much Do You Know About Biosimilars in China?
Test your knowledge of biosimilar approvals in China.
Poll: Which of the following is true about insulin products and the BPCIA?
Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.
Biosimilars Poll: Which Way Will the Supreme Court Rule on the ACA?
The court must decide whether Congress’ setting the shared responsibility payment to $0 means that the entire Affordable Care Act (ACA) statute is now unconstitutional.
Biosimilars Poll: What are the characteristics of a healthy biologics marketplace?
Opposing interests make it hard to define what elements are essential for a competitive marketplace.
Biosimilars Poll: What is Your Opinion on Clinical Efficacy Trials?
There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.
Biosimilars Poll: What Should Qualify for Interchangeable Status?
How quickly and easily biosimilars should be declared interchangeable with reference products has been an ongoing issue.
2 Clarke Drive Cranbury, NJ 08512